Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
Claes-Göran Östenson,1 Stephan Matthaei,2 Matthew Reaney,3 Thure Krarup,4 Bruno Guerci,5 Jacek Kiljanski,6 Carole Salaun-Martin,7 Hélène Sapin,7 David Bruhn,8 Chantal Mathieu,9 Michael Theodorakis10 1Department of Molecular Medicine and Surgery, Karolinska Ins...
Guardado en:
Autores principales: | Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c6b427517eeb4deabb630438e1dd8a79 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
por: Anichini R, et al.
Publicado: (2013) -
Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
por: Gurney K, et al.
Publicado: (2012) -
Twice-Daily Application of HIV Microbicides Alters the Vaginal Microbiota
por: Jacques Ravel, et al.
Publicado: (2012) -
Once and Twice
por: Richard S. Kayne
Publicado: (2015) - TWICE this week in consumer electronics.